// App-Quantinova.ai

: Regional analysis of COPD exacerbation rates in the DYNAGITO trial

Researchers

Presenter

  • Klaus F. Rabe

Principal Investigators

  • Jadwiga Wedzicha

  • Peter M.A. Calverley

  • Alberto De La Hoz

  • Florian Vo

  • Antonio Anzueto

  • Christine Jenkins

Medical Centers

  • LungenClinic Grosshansdorf, Grosshansdorf, Germany

  • National Heart and Lung Institute, Imperial College London, London, United Kingdom

  • Clinical Science Centre, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom.

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim Am Rhein, Germany

  • Department of Pulmonary Medicine and Critical Care, University of Texas Health Sciences Center and South Texas Veterans Health Care System, San Antonio, TX, United States.

  • The George Institute for Global Health, The University of Sydney, Sydney, Australia

Locations

  • Germany

  • United Kingdom

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Tiotropium/olodaterol

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • NCT02296138

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved